Evidence map›Paper›PMID 40227675›Full record

ArticleCancers2025

Implementation of a Traceback Testing Program for Ovarian Cancer: Findings from the FACTS Study.

Nora B Henrikson, M Cabell Jonas, Paula R Blasi, Adam H Buchanan, Pim Suwannarat, Kathleen Leppig, Aaron Scrol, Tracey Leitzel, Adrienne N Deneal, Daniela Canedo and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Nora B HenriksonKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, USA.ORCID 0000-0002-3459-7787
M Cabell JonasMid-Atlantic Permanente Research Institute, 700-B 2nd Street NE, Washington, DC 20002, USA.
Paula R BlasiKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, USA.ORCID 0000-0002-7094-706X
Adam H BuchananGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.ORCID 0000-0002-6518-2453
Pim SuwannaratMid-Atlantic Permanente Research Institute, 700-B 2nd Street NE, Washington, DC 20002, USA.
Kathleen LeppigDivision of Medical Genetics, Department of Medicine, University of Washington, 1705 NE Pacific St., Seattle, WA 98195, USA.
Aaron ScrolKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, USA.
Tracey LeitzelGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.
Adrienne N DenealMid-Atlantic Permanente Research Institute, 700-B 2nd Street NE, Washington, DC 20002, USA.ORCID 0009-0008-1037-6497
Daniela CanedoMid-Atlantic Permanente Research Institute, 700-B 2nd Street NE, Washington, DC 20002, USA.
Arvind RamaprasanKaiser Permanente Washington Health Research Institute, 1730 Minor Ave, Suite 1360, Seattle, WA 98101, USA.
Sundeep S BasraMid-Atlantic Permanente Research Institute, 700-B 2nd Street NE, Washington, DC 20002, USA.ORCID 0000-0003-0040-9896
Jennifer BrownMid-Atlantic Permanente Research Institute, 700-B 2nd Street NE, Washington, DC 20002, USA.
Marilyn OdumsMid-Atlantic Permanente Research Institute, 700-B 2nd Street NE, Washington, DC 20002, USA.
Yirui HuGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.
Katrina M RomagnoliGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.
Estella KhieuSwedish Health Services Maternal and Fetal Specialty Center, Seattle, WA 98104, USA.
Elsa BaltonDivision of Medical Genetics, Department of Medicine, University of Washington, 1705 NE Pacific St., Seattle, WA 98195, USA.
Saumya PatelGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.
Muki KunnmannGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.
Dina HassenGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.ORCID 0000-0002-4385-2233
Jing HaoGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.ORCID 0000-0001-9332-3842
Meredith LewisGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.
Rachel SchwiterGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.
Jessica GoehringerGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.ORCID 0000-0002-6708-8399
Heather M RameyGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.
Shanshan GustafsonMid-Atlantic Permanente Research Institute, 700-B 2nd Street NE, Washington, DC 20002, USA.ORCID 0000-0002-5995-5560
Katrina HsiehMid-Atlantic Permanente Research Institute, 700-B 2nd Street NE, Washington, DC 20002, USA.
Ilene LaddGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.
Alanna K RahmGeisinger Department of Genomic Health, 658 Center Street, Danville, PA 17822, USA.ORCID 0000-0003-2513-9298

Funding

Feasibility and Assessment of a Cascade Traceback Screening program - FACTSU01CA240747 · NCI · GEISINGER CLINIC · PI BUCHANAN, ADAM H, HENRIKSON, NORA B. · 2020 to 2023
$2.9M
NCI NIH HHS U01 CA240747NIH HHS 5U01CA240747-04X1
6 · The paper itself

Abstract

methodsWe conducted a multisite, nonrandomized pilot implementation study of a Traceback program at three integrated United States health systems. We assessed the reach, fidelity, effectiveness, and acceptability of the program using quantitative and qualitative methods.

resultsWe identified 597 eligible individuals using administrative data and manual chart review. We attempted to reach everyone identified (100% fidelity). We successfully contacted 354 people, for a reach of 59% of confirmed eligible individuals. In total, 133 people completed Traceback genetic testing. Ten of these (8%) received pathogenic or likely pathogenic results;. Nine of these ten people received positive results for which cascade testing of at-risk relatives would be indicated. None of their relatives underwent cascade testing during the study period. Thirty-six received variants of uncertain significance (VUS). Traceback programs were acceptable to participants and implementers and thought to be applicable to other genetic screening conditions. The time and resources required to accurately identify Traceback-eligible individuals are likely determinants of future sustainability.

conclusionsEducation about free cascade testing, reminder calls to probands, and offers to directly contact at-risk relatives did not result in cascade testing in this pilot study. However, participant and implementer discussions suggest that the potential benefits of Traceback programs and high participant acceptability are worthy of further study.

Indexed as

cancer preventiongynecologic cancer risk reductionovarian cancer

Identifiers

PMID40227675
PMCPMC11988076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.